PATH’s history in cervical cancer prevention

For over two decades, PATH has been at the forefront of efforts to build an evidence base for appropriate cervical cancer prevention interventions, to share lessons related to successful strategies, and to provide technical assistance to countries interested in making progress in cervical cancer prevention.

Fueled by a recognition of the inequitable burden of cervical cancer in low-resource countries, access to human papillomavirus (HPV) vaccines for young women is expanding at an unprecedented pace. Simultaneously, new screening and treatment alternatives for adult women are on the rise. For the first time in history, it appears that elimination of cervical cancer is within reach.

Technical assistance for country HPV vaccine programs

PATH currently provides technical assistance to countries for the planning, implementation, and evaluation of national HPV vaccination programs. This work builds upon six years (2006–2012) of successful formative research, clinical studies, and vaccination demonstration programs in India, Peru, Uganda, and Vietnam (http://www.rho.org/HPV-practical-experience.htm).

Since 2012, the PATH Center for Vaccine Innovation and Access has received funding from Gavi, the Vaccine Alliance (Gavi) to support country introductions of HPV vaccine through two pathways: demonstration programs and national introductions (www.gavi.org/Support/NVS/Human-papillomavirus-vaccine-support). To date, PATH has supported demonstration programs in 27 countries and assisted 13 countries in national introductions (see map).

The PATH HPV technical assistance team includes staff based in Africa, Europe, and the United States. Our HPV technical assistance work complements PATH’s Cervical Cancer Prevention project focused on screening and pre-cancer treatment.

To increase access to HPV vaccines, PATH has close collaborations with local nongovernmental partners and ministries of health that are integral to this effort. In addition, PATH works closely with partners around the world. These partners include Gavi, the World Health Organization (WHO), United Nations Children’s Fund (UNICEF), United Nations Population Fund (UNFPA), Bill & Melinda Gates Foundation (BMGF), the United States Centers for Disease Control and Prevention (CDC), John Snow International (JSI), the Clinton Health Access Initiative (CHAI), Jhpiego, and GirlEffect.

PATH provision of HPV vaccine technical assistance (as of September 2018*)

*PATH currently supports 7 countries: Ethiopia, The Gambia, Mauritania, Senegal, Solomon Islands, Uganda, and Zimbabwe.
**Technical assistance work streams**

The PATH HPV technical assistance team’s activities are channeled through four primary work streams: Gavi application support, program planning and implementation, evaluation, and cervical cancer prevention and control strategies (see below). Throughout this work, the team coordinates with global and in-country partners, capitalizing on the strengths of each partner’s country presence and technical capacities to ensure the success of Gavi-supported HPV vaccination programs.

**Gavi application support**

The PATH HPV technical assistance team assists countries that are preparing applications for Gavi funding. Team members work closely with countries to review the Gavi program and its requirements, map out a preliminary strategy for the country program, prepare content and data needed, and assist the country with submitting a quality application.

**Program planning and implementation**

The HPV technical assistance team also assists countries in their Gavi-supported HPV vaccination program planning. This work typically starts by designating an in-country technical advisory group to provide program guidance. The team can assist countries with all aspects of program planning: identifying the target population and vaccine delivery strategies; determining appropriate vaccination venues and logistics; estimating costs and budgets; reviewing implementer roles and training plans; developing job aids; conducting training of health workers and teachers; developing communication materials and social mobilization strategies; revising recording and monitoring tools; and preparing for supportive supervision and evaluation.

The PATH team also supports countries as they put their HPV vaccination program plans into action. During implementation, PATH offers technical assistance such as real-time program support, review, and monitoring during the initial rollout phase of the first dose, feedback on delivery challenges and problem-solving, and program adjustments for improvements.

**Evaluation**

Ensuring quality program evaluation is a key component of the PATH HPV technical assistance team’s support. Team members work with countries to plan and implement an appropriate program evaluation to meet the needs of the country, e.g., community-based vaccination coverage surveys, post-introduction evaluation of feasibility of vaccine delivery, and micro-costing analyses of the financial and economic costs of HPV vaccine delivery.

**Cervical cancer prevention and control strategies**

The HPV technical assistance team works closely with our PATH Reproductive Health colleagues and other partners to support country efforts to strengthen comprehensive cervical cancer prevention and control efforts. Assisting countries to translate international guidance for best practices in screening and treatment, facilitating introduction of technologies such as DNA-based HPV testing, and validating new methods for screening or precancer treatment are three efforts PATH is engaged in. For more information, see the publications Cervical cancer screening and treatment in low-resource settings (www.rho.org/HPV-screening-treatment.htm) and Current PATH Initiatives in Cervical Cancer Prevention (https://path.org/resources/current-initiatives-in-cervical-cancer-prevention/).

**The global effort to introduce HPV vaccines**

This work is part of a larger effort to introduce HPV vaccines in low- and middle-income countries around the world. Since HPV vaccines first became available in 2006, more than 100 countries and territories have introduced HPV vaccines into their national immunization programs. This progress has been made possible through efforts from international organizations, governments, foundations, nongovernmental organizations, civil society groups, and other stakeholders.